MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Cumberland Pharmaceuticals Total Assets 2011-2026 | CPIX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Cumberland Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75.6 M | 81.8 M | 92.9 M | 84.5 M | 96.5 M | 105 M | 113 M | 93.2 M | 93.4 M | 91.9 M | 95.4 M | 87.6 M | 98.6 M | 95.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 113 M | 75.6 M | 93.2 M |
Quarterly Total Assets Cumberland Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65.9 M | 67.9 M | 69.9 M | 75.6 M | 76.7 M | 78.5 M | - | 81.8 M | 87.8 M | 89.4 M | 89.5 M | 92.9 M | 90.8 M | 92.5 M | 96.7 M | 84.5 M | 87.6 M | 88.9 M | 93.3 M | 96.5 M | 96.5 M | 96.5 M | 96.5 M | 105 M | 104 M | 105 M | 115 M | 113 M | 113 M | 113 M | 113 M | 93.2 M | 93.2 M | 93.2 M | 93.2 M | 93.4 M | 93.4 M | 93.4 M | 93.4 M | 91.9 M | 91.9 M | 91.9 M | 91.9 M | 95.4 M | 95.4 M | 95.4 M | 95.4 M | 87.6 M | 87.6 M | 87.6 M | 87.6 M | 98.6 M | 98.6 M | 98.6 M | 98.6 M | 95.5 M | 95.5 M | 95.5 M | 95.5 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 115 M | 65.9 M | 93.1 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M |  USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.1 | 3.78 % | $ 118 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
18.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Evolus
EOLS
|
226 M | $ 5.43 | 31.36 % | $ 350 M | USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.67 | 2.5 % | $ 1.38 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Harrow Health
HROW
|
399 M | $ 39.59 | 2.55 % | $ 1.46 B | USA |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 0.58 | 4.69 % | $ 10.1 M |  China |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.67 | 5.46 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.96 | 2.96 % | $ 390 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.77 | -1.68 % | $ 449 M | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
286 M | $ 12.24 | 2.9 % | $ 869 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 0.89 | -0.81 % | $ 20.8 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.59 | -2.44 % | $ 2.04 B | Canada |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.4 | 2.29 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
8.54 B | $ 11.62 | 2.06 % | $ 1.61 B | USA |
 |
Sundial Growers
SNDL
|
1.35 B | $ 1.55 | 1.31 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.24 | 0.94 % | $ 23.4 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 22.61 | 2.31 % | $ 1.05 B | USA |
 |
Veru
VERU
|
60.4 M | $ 2.61 | 3.57 % | $ 352 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
Viatris
VTRS
|
50 B | $ 14.71 | -1.24 % | $ 17.7 B | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.78 | -0.84 % | $ 3.36 M | USA |
 |
Relmada Therapeutics
RLMD
|
97.6 M | $ 4.76 | 1.93 % | $ 143 M | USA |
 |
SCYNEXIS
SCYX
|
128 M | $ 0.76 | 1.12 % | $ 36.4 M | USA |
 |
Solid Biosciences
SLDB
|
189 M | $ 6.2 | 3.94 % | $ 253 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 2.69 | -2.18 % | $ 3.34 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 7.49 | 1.7 % | $ 4.63 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |